Abstract | Whole-exome sequencing has emerged as a fast and effective tool for the elucidation of genetic defects underlying both rare and common human diseases. Increased availability and decreased costs of next-generation sequencing have enabled investigators to use this approach not only in individual patients with rare diseases, but also to screen large cohorts or populations for the genetic determinants of diseases. Within the field of endocrinology, exome sequencing has led to major advancements in our understanding of many disorders including adrenal disease, growth and puberty disorders and type 2 diabetes mellitus, as well as a multitude of rare genetic syndromes with prominent endocrine involvement. In this Review, we provide an overview of these new insights and discuss the role that exome sequencing is expected to have in endocrine research and future clinical practice.
Introduction
Since the completion of the Human Genome Project over a decade ago, 1 techniques for large-scale genomic analysis have continued to evolve from an individual gene-based approach to genome-wide analyses of d isease-causing determinants. An important advancement has been the development of whole-exome sequencing (WES) in the past 5 years. 2 WES is a highly effective form of high-throughput genetic analysis, in which >90% of the coding DNA of an individual is sequenced. 3 This coverage is accomplished by using 'exome capture' techniques, in which DNA probes that specifically target all of the exons in the genome are used to extract the protein coding portion from the remainder of the genomic DNA ( Figure 1 ). The exome represents ~1% of the entire genome and thereby enables a more cost-effective approach to the identification of mutations than whole-genome sequencing, which currently costs approximately sixfold more than WES. 4 The targeted DNA is then sequenced using next-generation sequencing technologies, and the patient's sequence is compared with the human reference genome for the identification of genetic variants. However, a substantial number of pathologic genetic aberrations in the regulatory regions of the genome, as well as in exons that are not captured, will be missed by exome sequencing, although the exact number is difficult to ascertain. Despite these limitations, the use of WES has been very successful in identifying novel genes and disease pathways.
One of the earliest examples is provided by exome sequencing studies in Kabuki syndrome. 5 In this poorly understood genetic syndrome of multiple congenital malformations with wide phenotypic variability, exome sequencing identified pathogenic mutations in KMT2D (formally known as MLL2) in >50% of patients. 5 The impressive advancement in our understandings of Kabuki syndrome is a striking example of how exome sequencing can reveal the cause of rare monogenic diseases (diseases in which a single genetic variant within an individual explains the phenotype).
Within endocrinology, the use of WES has identified the genetic aetiology for a number of rare syndromes with prominent endocrine components. Other applications include the study of large, population-based cohorts to identify more common, low-risk genetic variants that contribute to common polygenic diseases such as type 2 diabetes mellitus (T2DM). Finally, exome sequencing has enabled the identification of both germline and somatic mutations that lead to endocrine neoplasia ( Figure 1 ). In this Review, we describe the most prominent advancements resulting from each of these three approaches and discuss potential benefits and pitfalls of implementing WES into clinical practice.
Rare endocrine disorders
Many endocrine diseases are rare, and aside from their clinical description and management, relatively little is known regarding their aetiology factors or causative genes compared with more common disease such as T2DM. However, WES-based studies involving one or more affected individuals have produced remarkable new insights into gene function for these diseases ( Table 1 ).
conditions that lead to precocious, delayed or incomplete pubertal development. Hypothalamic go nadotrophinreleasing hormone (GnRH) neurons function as a pulse generator, leading to the initiation of gonadotropin release by the pituitary gland and thus pubertal development, but the specific genetic determinants that govern the individual timing of puberty were largely unknown. 6 In 2013, investigators performed WES in 40 patients from 15 different families with familial central precocious puberty (CPP) and identified loss-of-function mutations in the imprinted gene MKRN3 (which codes for probable E3 ubiquitin-protein ligase makorin-3) as the causal genetic factor. 7 Functional evidence for the involvement of this gene was provided by the demonstration of decreasing MKRN3 mRNA expression in murine hypothalami before the onset of puberty, which further supported a role for this gene as a repressor of pubertal onset. 7 In a follow-up study the clinical significance of MKRN3 mutations in a large independent cohort of 215 patients with CPP was confirmed and the question arises as to whether differential MKRN3 expression among children can explain the normal variation in pubertal timing. 8 On the basis of these findings, targeted sequencing of MKRN3 should be rapidly introduced into clinical practice to identify a molecular aetiology in cases of familial CPP and should also be considered in isolated cases of this endocrine disease.
WES has also enabled investigators to study the genetics of delayed puberty and hypogonadism. Kallmann syndrome, the combination of hypogonadotropic hypogonadism and anosmia, is the result of mutations in a number of genes involved in GnRH neuron migration from the olfactory placode to the hypothalamus during fetal development. 9 WES combined with auto zygosity mapping, a technique that identifies regions of the genome inherited from a common ancestor in a consanguineous family, and candidate gene screening were used to demonstrate homozygous loss-of-function mutations in the FEZF1 gene in four individuals with Kallmann syndrome from two independent families. 10 Functional evidence for the involvement of FEZF1 was identified using mice, in which this gene was found to be involved in olfactory receptor neuron migration into the CNS. 11 Similarly, four novel mutations (in PNPLA6, RNF216, Key points ■ Exome sequencing in rare familial endocrine syndromes has led to the identification of many disease-associated genes and unravelled new biological pathways ■ In large, population-based cohorts, the use of exome sequencing has identified common, low-risk genetic variants that contribute to common diseases such as type 2 diabetes mellitus and hyperlipidaemia ■ Exome sequencing has provided insights into the pathogenesis of neuroendocrine tumours ■ Exome sequencing has also been used to implicate increased protein kinase A activity in the development of Cushing syndrome and somatic ion channel defects in primary hyperaldosteronism ■ With lowering costs, increasing availability and high diagnostic yield, the use of exome sequencing in the care of patients with endocrine diseases is expected to increase rapidly in the coming years OTUD4 and STUB1), which lead to the neurodegenerative Gordon Holmes syndrome, a disorder characterized by hypogonadism and severe ataxia, have been identified. [12] [13] [14] [15] RNF216, OTUD4 and STUB1 are involved in the ubiquitination pathway, which suggests there could be an association between disordered ubiquitination and delayed puberty. [12] [13] [14] [15] PNPLA6 has a role in intracellular phospholipid homeostasis and mutations in this gene seem to interfere with gonadotropin release.
14 In other WES-based studies, new genes have been associated with familial cases of female gonadal dysgenesis and primary or premature ovarian failure after puberty, such as STAG3, PSMC3IP, EIF4ENIF1 and SYCE1. [16] [17] [18] [19] Familial glucocorticoid deficiency Until 2012, only mutations in the adrenocorticotropic hormone receptor, encoded by MC2R, and its accessory protein, encoded by MRAP, had been identified as genetic causes of familial glucocorticoid deficiency (FGD). 20 However, many investigators have now identified different pathways that lead to the same FGD phenotype using WES, including those involved in the mitochondrial detoxification of reactive oxygen species. [20] [21] [22] In a consanguineous family, which included seven individuals with FGD, WES was used to identify a novel homozygous mutation in TXNRD2, which codes for thioredoxin reductase 2, part of the thioredoxin antioxidant system. 22 Functional evidence for this gene's involvement in FGD was provided by a TXNRD2 knockdown adrenocortical cell line (NCI-H295R), which displayed a marked increase in reactive oxygen species production and increased susceptibility to oxidative stress compared with control cells. 22 Similar results have been reported for mutations in the nicotinamide nucleotide transhydrogenase (NNT) gene, which is crucial for the production of sufficient amounts of NADPH and required for adequate redox reactions by p450 enzyme systems in the adrenal cortex. 21 Moreover, in a genetically isolated population with FGD from Ireland, exome sequencing was used to identify the first human mutation in MCM4 (which encodes minichromosome maintenance deficient 4) as a cause of the adrenal insufficiency, short stature and natural killer cell deficiency associated with this disorder. 23 MCM4 is involved in DNA replication and its deficiency leads to cell cycle disturbances, genomic instability, increased cancer risk and developmental defects. 24, 25 For the studies implicating NNT and MCM4 in FGD, the investigators used genetically isolated populations and homozygosity mapping to identify candidate regions of the genome that harboured the causal mutations. 21, 23 The investigators then performed targeted sequencing of all the exons in those regions to identify the causal variants. This technique is particularly useful for identifying recessive disorders and enables researchers to focus the genomic investigation to a particular region of the genome, thereby further decreasing sequencing costs. These studies have provided important additional insights into basic adrenal physiology and highlight the increased susceptibility of the human adrenal gland to oxidative stress.
Novel endocrine disorders
Through a collaborative study in a large cohort of patients, loss-of-function mutations or deletions in the IGSF1 gene, which encodes the immunoglobulin superfamily member 1 protein, were identified by WES as the cause of a novel X-linked disease that consists of short stature, central hypothyroidism and macroorchidism. 26 This disease seems to be a rare condition with an estimated incidence of only one in 100,000. 27, 28 The immunoglobulin super family member 1 protein is a plasma-membrane glycoprotein that is expressed in the anterior pituitary gland and might have an important role in protein trafficking to the cell surface. 26, 29 Interesting results have also been reported from a study in the thyroid field, in which exome sequencing was performed in a consanguineous family with thyroid dysgenesis, a defect in thyroid gland development. 30 Surprisingly, a homozygous missense mutation was identified in SLC26A4, which had previously been associated with a thyroid dyshormonogenesis phenotype, a condition in which the thyroid gland is formed normally but thyroid hormone cannot be produced, thereby expanding the clinical spectrum of SLC26A4 gene mutations. 30 
Common endocrine disorders
Common endocrine disorders, such as T2DM, hyperlipidaemia and the metabolic syndrome, are highly poly genic, meaning that variants in multiple genes influence an individual's risk of developing these dis orders. Typically, these genetic variants are common in the population, found in >5% of individuals, and have only very small individual effects. 31 Genome-wide association studies (GWAS) have enabled the identification of polymorphisms and genomic loci that are associated High-throughput sequencing
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Germline mutations Figure 1 | The use of WES to identify mutations. a | Genomic DNA is isolated from a patient and fragmented. DNA-based exon-specific adaptors ligate to the coding sequences in the DNA. Unligated fragments, which represent the noncoding DNA are removed and the exon-adaptor combinations amplified to increase copy number. The amplified fragments are sequenced using high-throughput sequencing techniques. Multiple sequence reads from a patient are compared with a reference genome sequence from which a pedigree of variant inheritance can be determined. b | In paired WES, genomic DNA is isolated from the blood and a tissue of interest, such as a tumour. After WES the two traces are compared to identify and differentiate between pre-existing germline or de novo somatic mutations. Abbreviations: spec., specific; WES, whole-exome sequencing.
with a trait of interest (for example, T2DM) and can also highlight relevant biological pathways involved in these diseases. However, in most cases, GWAS do not identify the actual causal risk variant, nor do they assess variants of lower frequency. 31 In this context, the use of WES has advanced our understanding of common endocrine disorders via two approaches. First, WES enables the identification of low-frequency coding variants that might only be present in small subsets of the population. 32 Second, by sequencing the exomes of individuals with an extreme presentation of a common disorder, rare variants with large effects in a specific gene might be identified, which will provide insights into the underlying pathophysiology of the common disorder (examples of such studies are shown in Table 2 ). An improved understanding of the genetic basis of familial dyslipidaemia and associated cardiovascular risks, the metabolic syndrome and T2DM can, therefore, have a major impact on health policy for both primary and secondary prevention in high-risk patient groups.
Cardiovascular endocrinology and dyslipidaemia WES has been performed to identify low-frequency genetic determinants of raised levels of LDL cholesterol. 33 This approach has successfully identified novel genes that were not previously linked to the risk of developing cardiovascular disease. For example, in the large, multicentre National Heart, Lung and Blood Institute Grand Opportunity Exome Sequencing Project in the USA, exome sequencing was performed on the DNA of 2,005 individuals, with a quarter of those having either the highest (>98 th ) or the lowest (<2 nd ) LDL-cholesterol percentiles ( Figure 2 ). 33 The exome sequencing was followed by the genetic analysis of an additional 1,302 people and genotyping of 52,221 individuals for selected genes. 33 An important role for low-frequency genetic variants in the PNPLA5 gene, which had not previously been associated with lipid abnormalities was identified, as well as an increased burden of rare variants in three known lipidassociated genes (PCSK9, LDLR and APOB). 33 In general, these rare variants had much larger effects on LDLcholesterol levels (~0.62-3.00 mmol/l) than the common variants identified by GWAS and together might explain the considerable variability in LDL-cholesterol levels in this population.
Additionally, insights from patients with extreme symptoms of a common disorder might help improve our understanding of the underlying pathophysiology and enable the development of novel therapies. Such patients are likely to be enriched for genetic variants that contribute to the common disorder and thereby facilitate gene discovery in a small sample size (Figure 2 ). For example, a combined linkage analysis with WES data from 16 individuals in a five generation family was used to identify a novel missense variant in SLC25A40 (c.374A>G) as a contributing genetic factor of severe hyper triglyceridaemia. 34 In this study, the investigators again used data from the National Heart, Lung and Blood Institute Exome Sequencing Project 33 to validate that individuals with rare nonsynonymous variants in SLC25A40 had increased triglyceride levels.
34 SLC25A40 encodes a solute carrier localized to the mitochondria; 35 however, its role in triglyceride regulation is currently unknown.
In another study, WES was used to identify novel mutations in a family of patients with hypobetalipoproteinaemia who were negative for the APOB mutations that are usually associated with this disorder. 36 In this study, compound heterozygous nonsense mutations (Ser17X, rs267606655; Glu129X, rs200785483) were identified in the ANGPTL3 gene, 36 which is involved in inhibition of lipoprotein and endothelial lipase and leads to raised plasma levels of HDL cholesterol and triglyceride in rodents. 37 Such studies might highlight genes that can be used as a therapeutic target. For example, although the initial studies did not use WES but rather traditional linkage mapping and candidate gene sequencing, 38 ,39 the identification of loss-of-function mutations in PCSK9 were associated with low levels of LDL cholesterol and a decreased risk of coronary heart disease. Consequently, a new class of cholesterol-lowering drugs targeting the PCSK9 protein have been developed. 40 
T2DM
In a large cohort study, the investigators used WES in 1,000 patients with metabolic phenotypes including T2DM, obesity and hypertension, and compared these results with those of 1,000 healthy individuals. 41 Two common coding variants that were associated with small but significant changes in risk of T2DM were identified: rs7607980 in COBLL1 (OR 0.88, P = 1.2 × 10 -11 ) and rs2296172 in MACF1 (OR 1.10, P = 8.2 × 10 -10 ). 41 The biological effect of these polymorphisms and how they relate to the disease biology is unknown. Another exome sequencing study that included 2,000 individuals from Denmark, half of whom had T2DM, did not identify any genes with an increased burden of rare nonsynonymous variants in patients with T2DM. 42 How ever, investigators in the deCODE group successfully used whole-genome sequencing of 2,630 individuals from Iceland followed by imputation into the larger Icelandic population (11, 114 Icelandic cases and 267,140 controls) to discover a low-frequency intronic variant in CCND2 (rs76895963), present in 1.47% of the population, which seems to reduce the risk of T2DM by half (OR 0.53, P = 5.0 × 10 -21
). 43 CCND2 encodes the cell cycle regulator cyclin D1, which controls pancreatic β-cell proliferation. 44 Additionally, these investigators identified two missense variants in PAM (rs35658696 OR 1.23, P = 3.9 × 10 -10 and rs78408340 OR 1.47, P = 1.7 × 10 -5 ) and a frameshift in PDX1 (p.Gly218Alafs*12 OR 2.27, P = 7.3 × 10 -7 ), which all increased the risk of T2DM. 43 The remarkably high incidence of T2DM among certain Hispanic populations in the USA has prompted researchers to use genome-wide approaches to search for determinants of T2DM risk among people from different ethnic backgrounds. 32 In a large collaborative study, investigators in the SIGMA type 2 consortium performed WES on 3,756 individuals from Mexican or Hispanic descent in the USA, ~50% of whom were known to have T2DM. ) between T2DM and a low frequency missense variant (c.1522G>A) in hepatocyte nuclear factor 1-alpha (HNF1A), a pancreatic transcription factor known to be involved in maturity-onset diabetes of the young type 3 (MODY3). 32, 45 Interestingly, in multi-ethnic replication studies, this specific variant is exclusive to the Hispanic population. 32 Patients with this particular variant were clinically indistinguishable from the remaining patients with T2DM. Although these results are preliminary, they are a good example of how WES might guide follow-up studies on screening practices in groups at high risk of developing common diseases with a heavy burden on population health, such as those with T2DM. Patients with classic MODY3 respond to sulphonylurea treatment; 45 consequently, WES might help identify patients who could benefit from this treatment as their underlying genetic defect leads to a primary deficiency in insulin production.
Height and growth disorders
In population-based GWAS, >400 genomic loci associated with height have been identified, which highlight multiple known and novel pathways involved in human growth. 46 However, these common genetic variants do not account for all of the decrement in height seen in individuals with short stature. 47 By identifying families with one or more members who have severe short stature of unknown origin, WES might enable the study of novel mechanisms in the highly heterogeneous group of patients with idiopathic short stature. For example, WES of multiple family members from three affected families with idiopathic short stature and an advanced bone age revealed novel heterozygous mutations in ACAN, which encodes aggrecan, a key proteoglycan in the extracellular matrix of the growth plate, and is involved in linear skeletal growth. 48 Notably, multiple common variants in 46 Osteoporosis WES has been used in a detailed study of five families with X-linked osteoporosis and fractures, which enabled the identification of pathogenic variants in PLS3 (which codes for plastin-3). 49 This protein is involved in the formation of filamentous actin bundles; a different PLS3 genetic variant was associated with osteogenesis imperfecta type 1A phenotype. 49 In the same study, analysis of a large population cohort from the Netherlands aged ≥45 years (n = 8,638) indicated that heterozygous female carriers of a rare PLS3 variant (rs140121121) had a significantly increased risk of fracture (OR 1.95, 95% CI 1.39-2.74, P <0.001). 49 The functional relevance of PLS3 mutations in X-linked forms of osteoporosis has also been confirmed by other investigators. 50 The exact mechanism of how PLS3 defects cause osteoporosis and increased fracture risk is unknown, but might be associated with altered mechanosensing by osteocytes leading to effects on bone remodelling.
Endocrine neoplasia
Somatic mutations in specific genes might lead to formation of a tumour, which can then accumulate further multiple mutations. The standard approach to identifying the tumour-initiating mutation is to perform paired exome or genome sequencing of tumour cells and unaffected lymphocytes (or normal biopsy tissue) from an individual patient. 51 When paired sequencing is performed in a cohort of individuals with the same type of tumour, mutations in genes common to that tumour can be identified that are likely to underlie the pathophysiolo gy of the tumour (Figure 1 ).
In addition to the identification of somatic mutations within tumour specimens, WES has been used to identify novel germline mutations, which place an individual at increased risk of endocrine tumour formation later in life, as seen for DICER1. 52 Tumours can also arise when a second, somatic, mutation occurs in the unaffected allele while germline mutations can lead to a chronic disease state from conception by constitutive activation of cell signalling machinery.
Adrenal hypercortisolism
Four large studies have used WES on adrenal tumourblood pairs in patients with adrenal Cushing syndrome, which identified a crucial role for genetic mutations involving the cAMP dependent protein kinase A catalytic subunit (PRKACA). [53] [54] [55] [56] In one study, WES of 25 tumour-normal pairs (22 adenomas and three carcinomas) revealed the presence of a somatic mutation (p.Leu206Arg) in PRKACA in six samples. 53 This mutation was then found in an additional seven of 38 adrenal tumours. Functional studies were subsequently performed that demonstrated that this mutation leads to an increase in cAMP signalling. 53 In another study, WES in 49 tumour-blood pairs and RNA sequencing in 44 tumour samples identified a Leu205Arg mutation in PRKACA in 70% of adrenocortical adenomas. Similarly striking results were found for recurrent DOT1L mutations in macronodular hyperplasia and CLASP2 mutations in adrenocortical oncocytomas. 55 Other investigators have examined a large number of adrenocortical carcinomas (n = 45), a group of tumours known to have genetic heterogeneity. 57 A combination of WES and single nucleotide polymorphism array analysis identified recurrent alterations in both known and previously unknown genes (such as ZNRF3 in the β-catenin pathway), which was subsequently validated in an independent cohort of 77 adrenocortical carcinomas. 57 The investigators also distinguished two separate genetic subgroups of adrenocortical carcinomas, which differed in their biological behaviour and prognosis. Adrenal cortisol production is known to be mediated by cAMP, but the results of these studies independently show that mutational activation of this pathway leads to overt Cushing syndrome.
Similarly, the investigators of two different studies reported inactivating mutations in the ARMC5 gene in the majority of studied patients with bilateral macronodular adrenal hyperplasia (BMAH) for both the familial and isolated forms of the disease. 58, 59 Genetic evaluation of tumour-blood pairs in a group of 33 patients with BMAH identified germline and somatic inactivating ARMC5 mutations in 18 of the 33 patients. This inheritance pattern is consistent with the two-hit model (that is, an inherited germline mutation with a secondary somatic mutation in the tumour) commonly seen in tumour suppressor genes. Even though the exact function of ARMC5 is unknown at present, in vitro studies indicate an important role in steroidogenesis, as well as global effects on gene transcription, cellular growth and survival. 60 Importantly, the significance of ARMC5 mutations in BMAH was independently demonstrated Figure 2 | Identifying low frequency variants using WES. A common strategy is to select individuals from the extremes of the population distributions for a given trait. For example, those with very high and low LDL-cholesterol levels who have a higher probability of carrying genetic variants with greater phenotypic effects than patients in the middle of the distribution. Abbreviation: WES, whole-exome sequencing.
by a study, in which four of five families with members who had BMAH harboured an ARMC5 mutation. 59 These advances in our basic understanding of adrenocortical disease will help translational-medicine-based research to develop new selective, tumour-targeted therapies.
Primary hyperaldosteronism
Primary hyperaldosteronism is the most common cause of secondary hypertension, accounting for ~10% of all patients with hypertension. 61 Primary hyper aldosteronism results from either classic Conn syndrome (an adenoma) or bilateral adrenal hyperplasia of the zona glomerulosa. 62 Few discoveries have been made in the field of Conn syndrome since its description in 1955; 63 however, a WES-based approach was used to identify somatic mutations in the KCNJ5 gene in 40% of all patients with this disorder. 64 The KCNJ5 gene encodes the G protein-activated inward rectifier potassium channel 4 in the adrenal zona glomerulosa cells, which is involved in aldosterone biosynthesis. 62 Constitutional activation of this channel leads to increased intracellular calcium levels and ultimately to adrenal hyperplasia or adenoma formation. 62 When present as a germline gainof-function point mutation, the same KCNJ5 mutation responsible for causing Conn syndrome leads to familial hyperaldosteronism type 3 with bilateral adrenal hyperplasia, childhood hypertension and severe hypokalaemia from an early age (<7 years) onwards.
62,65 WES has also been used to implicate several other genes, including ATP1A1, ATP2B3 and CACNA1D, in the same pathophysiologic process of ion channel dysfunction that leads to primary hyperaldosteronism. 66, 67 Other neuroendocrine tumours WES-based studies have also enabled investigators to gain additional insights into the pathophysiology of other endocrine tumours, including parathyroid adenoma, nonfunctioning pituitary adenoma, phaeochromocytoma, paraganglioma and insulinoma (Table 3) . [68] [69] [70] [71] [72] For example, DICER1 is a member of the ribonuclease III family involved in microRNA generation and mutations in this gene lead to a well-described hereditary cancer syndrome. 73 Sahakitrungruang and colleagues performed paired blood-tumour WES in a 12-month-old infant with a pituitary blastoma resulting in Cushing disease, and identified a novel germline frameshift mutation in DICER1 together with an additional somatic missense mutation in the pituitary tumour cells. 52 
WES in clinical endocrinology
The primary benefit of WES, as opposed to candidate gene sequencing, is that it enables the unbiased simultaneous screening of ~20,000 genes. 2 Endocrinologists often treat patients with a suspected genetic aetiology of their disorder, yet the clinician is unable to identify a specific syndrome or candidate gene. In such cases, WES might be particularly beneficial. These patients might also have milder forms of known diseases or novel disorders. For example, using WES, our own group identified a known pathogenic mutation in FAM111A, which leads to Kenny-Caffey syndrome in a patient with idiopathic short stature. 74 Kenny-Caffey syndrome is characterized by short stature, impaired dentition, myopia and severe neonatal hypocalcaemia. 75 The single patient in our study did not have hypo calcaemia and consequently, a diagnosis of Kenny-Caffey syndrome was not initially considered despite the presence of the other features of the disorder. Using WES, we were able to make the diagnosis in <1 h after receipt of the sequence data. This example highlights the utility of WES for identifying the source of sporadic incidents of disease as opposed to familial cases with multiple affected family members. However, many diagnoses and novel insights into disease pathophysiology can still be made using WES in single patients. In those cases, detailed clinical phenotyping is essential as clinicians and investigators from different groups will need to compare genotype and phenotype data in order to facilitate novel gene discovery.
However, caution should be used when interpreting WES data. WES identifies tens of thousands of genetic variants in each individual; the majority of these variants are common in the general population and are, therefore, unlikely to cause or have large effects on either rare or common diseases. 76 Large-scale genomic sequencing projects have enabled the development of publicly available databases where one can simply search for the frequency of a genetic variant in a given population. Commonly used databases include the 1000 Genomes Project, 77 the National Heart, Lung, and Blood Institute Exome Variant Server 78 and the Exome Aggregation Consortium browser. 79 However, despite the availability of these sequencing databases, each individual patient will still have many rare and novel genetic variants not present in the databases that require interpretation. For example, in one study using data from the 1000 Genomes Project, each individual in the database of European REVIEWS ancestry had on average 112 novel variants including 68 missense variants and one nonsense variant in their exome. 80 Many of these novel variants will be in genes that might, theoretically, be linked to a patient's disease but are in fact benign polymorphisms. Consequently, rigorous assessment of each polymorphism is needed before concluding that the variant is contributing to the patient's condition.
For optimal interpretation of WES data, parental samples, in addition to the patient's sample, are particularly useful; this strategy is referred to as trio sequencing. 76 Parental samples are often available for paediatric patients but are much more difficult to obtain in adults. Trio sequencing enables the identification of de novo variants versus inherited ones. The method can also determine if two variants in the same gene are present on different copies of the chromosome and potentially cause a recessive disorder; that is, each variant was inherited from a different parent. 76 These analyses are particularly useful for evaluating rare disorders where the genetic variant is expected to segregate with the disease phenotype in the family, as demonstrated in the Kabuki syndrome discovery mentioned earlier in the text. 5 However, the actual penetrance of many genetic mutations that cause disease is unknown. In a striking example, a group of investigators used samples from the Framingham and Jackson Heart Studies and sequenced seven genes (GCK, HNF1A, HNF4A, HNF1B, INS, NEUROD1 and PDX1,) known to cause MODY, a monogenic form of diabetes mellitus. 81 In this study, ~1.5% of individuals had mutations in these genes, which have been reported as pathogenic, but the majority of carriers were euglycaemic and had no symptoms of MODY. As WES becomes more widely used by clinicians, many more reportedly pathogenic genetic variants will be identified and until a larger evidence base can be amassed, prognostication based on these variants will be difficult.
In addition to identifying variants in genes related to the patients' phenotype (that is, the reason the test was first ordered), WES has the potential to uncover incidental findings such as a predisposition for cancer or potential latent cardiomyopathy. In 2013, the American College of Medical Genetics published a list of 57 genes for which they believe clinical laboratories should report incidental findings. 82 Examples include BRCA1 and BRCA2 for hereditary breast and ovarian cancer, MEN1 for multiple endocrine neoplasia type 1 and MYBPC3 for cardiomyopathy. This recommendation has been controversial, as often the true clinical impact of finding novel or rare variants in these genes is not known and not all institutions insist on or carry out such reporting. 83 In one study, 3% of patients who underwent WES had medically actionable incidental findings in genes recommended for reporting by the American College of Medical Genetics. 84 Whether identifying these variants will have a positive effect on the health of patients has yet to be determined.
Nevertheless, WES is a powerful tool that is rapidly changing the diagnostic approach for patients with rare disorders that might have a genetic aetiology. The use of WES has been most widespread in the diagnosis of children with neurodevelopmental issues or multiple congenital anomalies and most series report that ~25% of patients can be diagnosed using WES. 76, [84] [85] [86] With the expected improvements in next-generation sequencing techniques and data analysis, as well as the increased availability of human genome data, this percentage might well rise in future studies. Clearly, the clinical use of this approach will vary depending on the specific patient characteristics. For example, the use of WES was able to establish a likely diagnosis in more than one-third of patients with a 46,XY disorder of sexual development, a highly heterogeneous condition that is often difficult to diagnose. 87 Another clinical area in which WES might be used is for the diagnosis of children with severe short stature and for whom a molecular diagnosis might affect treatment decisions and improve prognosis. 74, 88, 89 One limitation of WES is that it does not always provide uniform sequencing coverage (currently estimated at 85-95% of targeted sequence 76 ), whereas targeted diagnostic panels have been validated to ensure adequate coverage of all targeted exons. Moreover, WES does not permit robust determination of copy number variants (deletions and duplications) and targeted analysis for a candidate gene might still be necessary. 2 Furthermore, tumour sequencing is rapidly becoming a standard method in the treatment of cancer, with the hope that molecular characterization of tumours will enable clini cians to optimize chemotherapeu tic regi mens. 51 These advances will in turn influence the tr eatment of endocrine malignancies in the future.
Finally, we believe that at this time the utility of WES for determining a prognosis in common polygenic endocrine disorders remains quite limited. The majority of the genetic determinants to these dis orders are common variants found in noncoding regions outside the exome, and consequently WES will provide limited prognostic information. While some notable exceptions do exist, such as the HNF1A variant found in Hispanic populations, 32 the lack of data surrounding variant penetrance and difficulties with interpretation of WES data in the setting of common diseases make the likelihood of this method becoming a standard part of the routine endocrine evaluation doubtful. However, as whole-genome sequencing becomes cheaper and larger well-phenotyped populations of patients are studied, genetic risk profiles for common diseases that include information from noncoding regulatory, as well as rare coding, variants will probably become commonplace.
Conclusions
WES has enabled a huge leap forward in our understanding of the pathophysiology of endocrine disease. By elucidating the genetic aetiology of rare endocrine disorders, the use of WES has provided insights into the biological pathways underpinning all areas of endocrinology and opened up many new pathways for research. In the shortterm, these insights will be extremely beneficial for the diagnosis of rare endocrine disorders. More importantly, these discoveries will permit the development of novel therapeutic strategies in common endocrine disorders as well as in endocrine neoplasia. However, gene discovery is just the first step towards improved patient care and much work is still needed to realize the full potential of these initial genetic insights. We anticipate that the use of WES in clinical endocrinology will continue to expand, but will be primarily focused on patients with un diagnosed rare conditions.
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